Acute respiratory distress syndrome (ARDS) is a life-threatening ailment characterized by severe lung injury involving inflammatory cell recruitment to the lung, cytokine production, surfactant dysfunction, and up-regulation of nitric oxide synthase 2 (NOS2) resulting in nitric oxide (NO) production. We hypothesized that NO production from NOS2 expressed in lung parenchymal cells in a murine model of ARDS would correlate with abnormal surfactant function and reduced surfactant protein-B (SP-B) expression. Pulmonary responses to nebulized endotoxin (lipopolysaccharide, LPS) were evaluated in wild-type (WT) mice, NOS2 null (−/−) mice, and NOS2-chimeric animals derived from bone marrow transplantation. NOS2 −/− animals exhibited significantly less physiologic lung dysfunction and loss of SP-B expression than did WT animals. However, lung neutrophil recruitment and bronchoalveolar lavage cytokine levels did not significantly differ between NOS2 −/− and WT animals. Chimeric animals for NOS2 exhibited the phenotype of the recipient and therefore demonstrated that parenchymal production of NOS2 is critical for the development of LPS-induced lung injury. Furthermore, administration of NO donors, independent of cytokine stimulation, decreased SP-B promoter activity and mRNA expression in mouse lung epithelial cells. This study demonstrates that expression of NOS2 in lung epithelial cells is critical for the development of lung injury and mediates surfactant dysfunction independent of NOS2 inflammatory cell expression and cytokine production.
surfactant, the lipoprotein mixture synthesized and secreted by lung epithelial cells (2, 3, 4) . Surfactant imparts mechanical stability to alveoli by lowering surface tension and allows the lung to remain open during normal breathing. Therefore, its absence contributes to alveolar collapse, increased shear stress on the lung parenchyma during respiration, and ultimately further lung injury, especially in the setting of mechanical ventilation (5) .
Surfactant is composed of over 90% lipid, as well as a number of important protein components, including surfactant proteins A (SP-A), B (SP-B), and C (SP-C). Although SP-B comprises only 1-2% of this mixture by weight, it is the most critical of the surfactant proteins for maintenance of normal surface-film function (6) . In animal models, genetic deficiencies of SP-B are incompatible with life (7) , and humans with inherited partial SP-B deficiencies develop severe chronic lung disease (8) . Decreased SP-B content has been observed in the lungs of human ARDS patients (9) and in mice subjected to models of acute lung injury (10, 11) , but the molecular basis for these in vivo findings has not been elucidated.
Nitric oxide (NO) has been recognized as an essential modulator of lung biology, as well as an important mediator of acute inflammation (12) . Three distinct NO-synthesizing isoenzymes have been identified: NOS1 (nNOS) and NOS3 (eNOS) are constitutively expressed, while NOS2 (iNOS) is the inducible isoform. NOS2 is expressed in lung parenchymal and inflammatory cells and is strongly up-regulated by inflammatory stimuli (12) . Increased NOS2 expression has been demonstrated in the alveolar macrophages of patients with ARDS (13, 14) and in human lung epithelial cells treated with inflammatory cytokines (15) . In animal models, mice with targeted disruption of NOS2 (NOS2 −/− ) exhibit less severe lung injury parameters in the setting of systemic endotoxemia than do wild-type control animals (16) . However, the effect of NOS2-derived NO production on physiologic lung and surfactant function in the setting of severe acute lung injury mirroring human ARDS has not been evaluated. Furthermore, the relative amounts of NOS2 expression in inflammatory vs. parenchymal cells of the lung has direct importance for the pathobiology of ARDS and has not been elucidated in the setting of severe lung injury.
In the present study, we investigate the hypothesis that the parenchymal production of NO from a specific NOS isoform, NOS2, adversely affects surfactant function through decreased SP-B expression, and secondarily, pulmonary function at distinct stages of a severe acute lung injury process. We used a previously described murine model of acute lung injury that resulted from nebulized endotoxin (10) , which displays many of the physiologic, biochemical, and immunologic properties of human ARDS, including physiologic lung dysfunction, surfactant dysfunction, and a marked increase in cellular inflammation and inflammatory cytokines.
MATERIALS AND METHODS

Experimental protocol
Mice were studied under a previously described protocol (10) approved by our institution's animal studies committee and were maintained in a pathogen-free facility. Non-transplanted male mice were studied at 7-9 weeks of age. Two genotype groups were studied: 12 C57BL/6 wild-type (WT) mice (Charles River Animal Supply) weight 24 ± 3 g; and 12 C57BL/6 NOS2 null (NOS2 −/− ) mice (Jackson Labs) weight 27 ± 4 g, were used in this study. Each genotype group was further divided into two treatment groups (n=6 each): (a) LPS-treated animals exposed to two doses of 10 mg nebulized, sonicated endotoxin spaced 24 h apart, and studied 48 h after first dose administration (LPS: Pseudomonas aeruginosa serotype 10, Sigma Chemical, St. Louis MO); and (b) control animals exposed to vehicle (nebulized saline) over the same time period. At the appropriate time, animals from each group were anesthetized and tracheostomized and had lung physiology measured with a computer-controlled small animal ventilator (Flexivent, SCIREQ Inc., Montreal, Canada) as described previously (10, 17) . Bronchoalveolar lavage fluid (BALF) and lung tissue were harvested and processed as described previously (10) .
Assessment of static and dynamic interfacial properties of surfactant films
Surfactant was isolated from BALF, and surfactant function (all samples 1 mg/ml) was assayed in vitro by pulsating bubble surfactometry (Electronetics, Amherst, NY) as described previously (10) .
Lavage fluid cytokine determinations
Levels of murine tumor necrosis factor (TNF)-α and interleukin (IL)-6 were determined in the cell-free BALF using enzyme-linked immunosorbent assays (ELISAs; Endogen Corp, Cambridge, MA). Assays were performed in duplicate on surfactant ultracentrifuge supernatants (sixfold concentrated) according to the manufacturer's instructions. The assay range for TNF-α is 50-2450 pg/ml with lower limit of detection 9 pg/ml. The assay range for IL-6 is 51-2000 pg/ml with lower limit of detection 7 pg/ml.
Northern blot analysis for SP-B
Total RNA was extracted from lung tissue, and 5 µg of total RNA was subjected to electrophoresis, transferred to a 0.45 µM pore-sized nylon membrane, and hybridized to radiolabeled SP-B (American Tissue Culture Collection, Rockville, MD) and GAPDH probes, as described previously (10) . Autoradiography was performed by exposure to X-Omat film (Kodak) at -80°C, and the intensity of bands was measured by scanning densitometry.
Immunohistochemistry of lung tissue samples
Immunohistochemistry for SP-B, NOS2, and CD45 (leukocyte common antigen) was performed as described previously (10, 29) .
Bone marrow transplantation (BMT)
Chimeric animals were derived using a protocol approved by our institution's animal studies committee. Donor NOS2 −/− or WT animals (described above, 8 weeks old) were killed, and bone marrow cells were harvested under sterile conditions from the femurs and tibias using PBS (containing 2% fetal bovine serum [FBS] , 1% penicillin, 1% streptomycin). Recipient NOS2 →WT]) were subjected to the same experimental protocols as outlined above.
Cell culture, plasmids, and reagents
The mouse clonal cell line MLE-15 was a generous gift of Jeffrey Whitsett, and cells were grown in culture, as described (18) .
To assess the effect of nitric oxide (NO) administration on SP-B mRNA levels, cells were grown to 80% confluence and fed with fresh medium containing either vehicle (NaOH) or 3 mM of the NO-donor DETA NONOate (Cayman Chemical, Ann Arbor, MI). Cells were harvested 0, 6, 12, and 24 h following treatment, and total RNA was extracted as described previously (19) . Northern blots were performed using a radiolabeled SP-B probe (10) and a 28S rRNA probe (to confirm equal loading) as described previously (19) .
To evaluate the effect of NO on SP-B transcription in MLE-15 cells, we obtained the murine SP-B promoter cloned into pCAT-Basic (p-1797/+42/CAT) as a generous gift from Jeffrey Whitsett (20) . To allow us to measure luciferase activity as a marker of SP-B promoter activity during transient transfections, we inserted the SP-B promoter from this construct into the SmaI-XhoI sites of plasmid pGL2-basic (p-1797/+42/LUC). Transient transfections were performed by using FuGENE6 transfection reagent (Roche Molecular Biochemicals), as described previously (19) . Briefly, 2 × 10 5 cells/well were plated in triplicate in six-well plates and incubated for 24 h. Cells were then transfected with 1 µg of the SP-B promoter-reporter plasmid (p-1797/+42/LUC) and 0.5 µg of pCMV-βgal (Clontech, Palo Alto, CA) plasmid (to normalize for luciferase activity). On the following day, the cells were fed with fresh media containing either vehicle (NaOH) or the NO-donor DETA NONOate (0.5-1 mM). After 24 h of exposure, cells were harvested for luciferase and β-galactosidase activities. Luciferase activity was measured (Promega Luciferase Assay System) and normalized to β-galactosidase activity.
SP-A, SP-B, and SP-C isolation, purification, and reconstitution with surfactant from LPStreated WT mice
Purified calf SP-B and SP-A were isolated from calf lung surfactant as described previously (21) . SP-B and SP-C together were separated from other hydrophobic components by low-pressure chromatography using a 100 × 1.5 cm Sephadex LH-20 column and acidified chloroform methanol mobile phase. The fractions containing SP-B and SP-C were pooled, and the two proteins were then separated from one another by low-pressure chromatography using a 100 × 1.5 cm Sephadex LH-60 column using the same mobile phase. Effective separation of SP-B from SP-C was documented by SDS-PAGE performed on pooled fractions stained with silver nitrate.
Reconstitution studies were performed by adding physiologic equivalents of SP-A (5% by weight), SP-B (2% by weight), and SP-C (3% by weight) to surfactant from LPS-treated WT animals. 10 µg of purified calf SP-A in aqueous buffer was aliquoted into a microcentrifuge tube and dried under vacuum. Mouse surfactant (200 µg) in 200 µl of 5 mM CaCl 2 in saline was then added, and samples were mixed by repeated injection through a 27 g needle. 4 µg of purified calf SP-B in organic buffer was similarly aliquoted, dried, and reconstituted in aqueous surfactant. Synthetic SP-C in organic buffer was aliquoted and reconstituted in the same way. Samples were incubated at 37°C for 30 min, and function was then measured by pulsating bubble surfactometry as described above.
Statistical analysis
Results for each treatment group are summarized as mean values ± standard error (SE.).
Comparison of results between different groups at different time points was performed by twoway ANOVA (StatMost Software, Salt Lake City, UT). Statistical significance was defined as a P value < 0.05. Thus, LPS exposure caused physiological changes consistent with ARDS in WT mice, whereas NOS2 −/− animals were protected from the development of physiologic lung dysfunction. We next characterized in vitro surfactant function in both groups of animals.
RESULTS
Nebulized
Surfactant function is abnormal in LPS-treated WT mice but remains normal in LPStreated NOS2
−/− animals Dynamic surface tension vs. surface area profiles were measured in surfactant samples isolated from WT and NOS2 −/− mice ( Fig. 2 ). Prior to LPS exposure (vehicle group), surfactant function was normal and nearly identical in both groups of animals. In LPS-treated WT mice, the surfactant surface tension to surface area ratio increased, findings representative of significant dysfunction (curve shifted upward). In contrast, in NOS2 −/− mice, surfactant function was minimally affected by LPS exposure with a surface tension to surface area ratio similar to that of untreated animals.
Thus, differences in surfactant function measured in vitro in WT and NOS2 −/− mice correlate closely with differences in lung physiology observed in vivo. These results support the direct importance of NOS2 expression in the development of LPS-induced acute lung injury, manifested both in lung physiology measurements and surfactant function. We next determined SP-B expression in whole lungs isolated from WT and NOS2 −/− animals.
LPS treatment induces a NOS2-specific reduction of SP-B
Our previous study demonstrated that LPS-treated WT animals exhibit decreased SP-B lung content compared with control animals, whereas levels of SP-A and SP-C were not affected by LPS treatment (10) . We therefore assessed SP-B mRNA levels in lung tissue of WT and NOS2
−/− animals using Northern blots (Fig. 3A) . In WT mice, SP-B mRNA decreased 87% following LPS exposure, whereas in NOS2 −/− mice, LPS exposure had no significant effect on SP-B RNA levels. Lung immunostaining was performed for NOS2, SP-B, and CD45 in WT and NOS2
−/− animals ( Fig. 3B ). NOS2 staining was absent in both groups of vehicle-treated animals (a-b). NOS2 staining was present in both parenchymal and inflammatory cells in LPS-treated WT mice (c), while, as anticipated, NOS2 staining was absent in the LPS-treated NOS2 −/− mice (d). SP-B staining was present in alveolar epithelial cells (arrows) in both vehicle-treated WT and NOS2
animals (e-f). SP-B content was significantly reduced in LPS-treated WT animals (g). In contrast, LPS-treated NOS2 −/− animals retained SP-B expression (h), which was unchanged from vehicle-treated animals. LPS-treated WT and NOS2 −/− animals showed equivalent staining for
Our results demonstrate that surfactant dysfunction in WT mice following LPS exposure corresponds with induction of NOS2 expression and relates directly to a decrease in SP-B content. Conversely, maintenance of normal surfactant function in NOS2 −/− mice following LPS exposure is associated with maintenance of normal SP-B levels in the absence of NOS2 induction. We next determined whether a difference could be found in inflammatory cell recruitment or cytokine production in the lungs of the LPS-treated NOS2 −/− animals when compared with similarly treated WT mice.
BAL cell counts and cytokine levels do not differ between the LPS-treated NOS2
−/− and WT animals Total cell counts, cell count differentials, and cytokine levels were measured in bronchoalveolar lavage (BAL) fluid (Fig. 4) . BAL recovery was 94 ± 2% for WT mice (n=6 per treatment group) and 95 ± 2% for NOS2 −/− mice (n=6 per treatment group; P=NS). At baseline, WT and NOS2 −/− ).
Levels of interleukin (IL)-6 were undetectable in control (vehicle-treated) animals and were significantly elevated to a similar degree both in WT and NOS2 −/− animals following 48 h of LPS treatment (Fig. 4B , control WT and NOS2 −/− : IL-6 <7 pg/ml; LPS-treated WT and NOS2 −/− : IL-6 >2000 pg/ml). Based upon the described previously time course of tumor necrosis factor (TNF)-α elevation in BAL fluid following inflammatory stimuli (10), levels of TNF-α were measured in BAL fluid 2 h following LPS exposure and increased to equivalent levels in both groups of animals ( Fig. 4B , control WT and NOS2 −/− : TNF-α <9 pg/ml; LPS-treated WT and NOS2 −/− : TNF-α >2450 pg/ml).
These findings indicate that the failure of NOS2 −/− mice to develop physiological changes consistent with severe lung dysfunction following LPS exposure is not the result of a blunted inflammatory response nor of a suppressed release of inflammatory cytokines. We next evaluated whether NOS2 expression in inflammatory cells or in parenchymal cells was critical for the development of LPS-induced acute lung injury.
NOS2 expression in lung parenchymal cells is critical for the development of LPS-induced acute lung injury
Bone marrow transplantation (BMT) was used to derive chimeric animals for NOS2 (NOS2 (23, 24) . These chimeric animals were subjected to LPS nebulization and the experimental protocol described above. . When subjected to the experimental protocols as described above, the lung physiology measurements of these nonchimeric animals were indistinguishable from untransplanted age-matched WT and NOS2 −/− animals, respectively (data not shown).
Furthermore, the LPS-induced increase in lung elastance (H) was not significantly different in WT→WT mice (2.3 ± 0.03 fold increase in H) when compared with NOS2
−/− →WT mice (2.1 ± 0.10 fold increase in H, as described above).
Thus, these studies of chimeric animals reveal that NOS2 expression in epithelial cells is critical for the development of LPS-induced acute lung injury, while NOS2 expression in inflammatory cells does not influence the phenotype of the chimeric animal. We therefore evaluated whether nitric oxide, independent of inflammatory cytokines, decreases SP-B expression in lung epithelial cells in vitro.
Nitric oxide down-regulates SP-B message and promoter activity in lung epithelial cells
Northern blot analysis was performed on total RNA extracted from mouse lung epithelial (MLE-15) cells treated with the NO donor DETA NONOate (3 mM; N) or vehicle (V) (Fig. 6A) . SP-B mRNA decreased 19, 31, and 45% following NO exposure for 6, 12, and 24 h, respectively, when compared with vehicle (P<0.05 for 12 and 24 h). Transient transfections were performed using an SP-B promoter-reporter construct (P-1797/+42/LUC) in mouse lung epithelial cells treated with DETA NONOate (0.5 mM, 1 mM; N) or vehicle (0 mM; Fig. 6B ). SP-B promoter activity decreased by 48 and 62% with addition of 0.5 and 1 mM of DETA NONOate respectively (P<0.05 for each dose of DETA NONOate). NO donors did not shorten SP-B mRNA half-life (data not shown).
Taken together, these studies support an important role for parenchymal cell-derived NOS2 production of NO in transcriptionally down-regulating SP-B expression in the setting of endotoxin-induced acute lung injury. We therefore examined whether restoration of SP-B would restore normal surfactant function to the LPS-treated WT animals.
SP-B, but not SP-A nor SP-C, restores normal function to WT surfactant following LPS exposure
Reconstitution studies using SP-A, SP-B, and SP-C were performed to confirm the relationship between surfactant dysfunction and observed reductions in SP-B levels in LPS-treated WT animals. Surfactant samples from two LPS-treated WT mice were pooled, and surfactant function was analyzed at baseline, as well as following addition of physiological equivalents of SP-A, SP-B, or SP-C (Fig. 7) . The addition of SP-B restored significant function to abnormal surfactant isolated from LPS-treated WT mice. In contrast, neither addition of SP-A nor of SP-C fully restored normal surfactant function. These findings confirm that the majority of dysfunction, which occurs in surfactant isolated from LPS-treated WT mice, is specifically related to decreased SP-B levels.
DISCUSSION
In this study we investigated the role of NOS2 in ARDS using a nebulized-endotoxin model of acute lung injury. Our results demonstrate that LPS-treated WT mice develop significant lung inflammation and lung injury characterized by physiologic lung dysfunction and surfactant dysfunction. Lung dysfunction in LPS-treated WT animals correlates with a marked decrease in SP-B lung tissue RNA levels and SP-B lung immunostaining. In contrast, NOS2
−/− mice exhibit nearly normal physiologic lung and surfactant function and retain normal SP-B levels following LPS exposure. Unexpectedly, the NOS2 −/− animals develop equivalent levels of lung inflammation and cytokine production to those of the WT animals, which suggests that inflammatory cell expression of NOS2 does not determine the development of physiologic lung injury in this model. In fact, using NOS2-chimeric animals derived from bone marrow transplantation, we confirmed that it is epithelial cell expression of NOS2 which drives the development of acute lung injury in these animals. Furthermore, our in vitro studies in lung epithelial cells show a direct role for NO in down-regulating SP-B mRNA levels and promoter activity. These observations support the hypothesis that NO, expressed specifically through parenchymal cell-NOS2, plays a critical role in modulating SP-B expression at a transcriptional level within the lung, and show that NOS2-mediated changes in the SP-B content of lung surfactant markedly affect lung function.
A critical observation in our study is that the extent of lung inflammation and production of inflammatory cytokines within BAL fluid was not different between the WT and NOS2
−/− animals subjected to 48 h of nebulized LPS. We examined a severe and diffuse model of lung injury that would enable us to correlate our biologic findings with measurements of physiologic lung dysfunction. Therefore, compared with other published models (25) (26) (27) , our mice developed increased lung inflammation and cytokine production and were studied at a much later time point following injury (48 h). Our model reflects severe lung injury, once inflammatory cell recruitment has occurred and overwhelming lung injury has developed, which mirrors the dire clinical presentation of patients with ARDS. Therefore, our findings complement and extend beyond those of others who found that inflammatory cell expression of NOS2 was critical for the development of microvascular protein leak during the first eight hours following sepsis (25) . In fact, our data supports the intriguing concept that NOS2 expression is critical in different celltypes at different times, depending on the phase or extent of lung injury. Thus, inflammatory cell expression of NOS2 appears to be important for microvascular protein leak during very early phases of lung injury, while parenchymal cell expression of NOS2 down-regulates SP-B expression and results in lung dysfunction in later-phase ARDS, once overwhelming inflammation has already developed.
In this model of acute lung injury the parenchymal cell expression of NOS2 and NO production is critical for the decline in SP-B levels following LPS treatment. While these findings were initially unexpected in light of the extensive lung inflammation which develops during acute lung injury, other groups have described a partial contribution of lung parenchymal cells to the expression of NOS2 and production of NO during systemic endotoxemia, which is associated with a much less severe lung injury profile than in our model (23, 28) . The administration of nebulized endotoxin in our model of acute lung injury results in direct delivery of LPS primarily to epithelial cells, and other investigators have reported abundant NOS2 expression in lung epithelial cells (29, 30) and specifically in type II pneumocytes (37) following inflammatory stimuli. Similarly, we found increased NOS2 staining in alveolar epithelial cells following nebulized LPS (Fig. 5Bd) . Therefore, we propose that following lung injury, compartmentalized production of NO from increased NOS2 expression in epithelial cells results in reduced SP-B expression within Type II pneumocytes. In vitro studies in mouse lung epithelial cells performed by us and recently by others (31) confirm that NO administration, apart from inflammatory cytokines, down-regulates SP-B RNA levels and promoter activity at a transcriptional level.
Taken together, these findings support a novel role for NOS2 in the pathobiology of lung injury. The effects of NO and its byproducts have been studied in many models of lung injury and have been shown both to protect and to decrease pulmonary surfactant activity through a variety of mechanisms, depending upon the biological conditions (38-40). In the setting of ARDS, it has traditionally been thought that NO generated by activated macrophages in response to bacterial stimulation is released into the extracellular environment. Here it can cause surfactant dysfunction by directly reacting with lipid and protein components through the generation of either peroxynitrite or hydroxyl radical (32, 33) . However, recent studies have shown that whole lung surfactant, at concentrations that approximate those present within the normal lung (≥1 mg/ml), is quite resistant to direct exposure to peroxynitrite and hydroxyl radical (32, (34) (35) (36) . These data, plus our current findings, suggest that extracellular free radical-mediated changes in surfactant composition may not be primarily responsible for modulating lung dysfunction in ARDS. Alternatively, NOS2 production of NO may be an important regulator of surfactant expression within the alveolar type II cell (parenchymal cell) by modulating the level of gene transcription. Our results support this new alternate role for NOS2, and suggest that changes in surfactant composition which occur during ARDS are related to the role of NOS2-derived NO as regulator of SP-B expression.
In summary, these data demonstrate that the NOS2 isoform of nitric oxide synthase plays a critical role in regulating the expression of SP-B, a protein essential for normal surfactant and lung function. Furthermore, NOS2 expressed in lung epithelial cells decreases the expression of SP-B during severe acute lung injury. These findings have direct implications with regard to the clinical management of ARDS and support new approaches to treatment apart from traditional strategies solely targeting the inflammatory cell response, which has often developed in an overwhelming fashion by the time clinical illness is manifested. Our results suggest that therapies for ARDS directed toward modulation of epithelial cell NOS2 and SP-B expression have the potential to ameliorate the disease process, even after the development of significant cellular inflammation. The development of more effective and syndrome-specific treatment strategies are desperately needed for this life-threatening illness. −/− mice at baseline (vehicle, blue) and after 48 h of LPS (red) exposure are shown. At baseline (vehicle), surfactant function was similar in both groups. Minimum surface tensions during film compression were less than 1 dyne/cm, maximum surface tensions were between 30 and 35 dynes/cm, and films demonstrated significant hysteresis dynamic cycling. After exposure to LPS, surfactant samples from WT mice demonstrated elevations in minimum surface tension to near 20 dynes/cm, maximum surface tensions between 60 and 70 dynes/cm, and decreased hysteresis (curves shifted upward). Surfactant isolated from NOS2 −/− mice still reached minimum surface tensions <1 dyne/cm and was qualitatively similar to control samples. −/− mice (n=6 in each group). Levels of TNF-α and IL-6 were undetectable in both groups of animals at baseline (vehicle). Following LPS exposure, both groups of animals exhibited a similar, significant elevation of both cytokines. Error bars refer to SE (TNF-α=tumor necrosis factor α; IL-6=interleukin-6; P=NS between LPS-treated WT and NOS2 −/− animals). . Minimum surface tension returned to <1 dyne/cm, and film hysteresis increased. Addition of synthetic full length SP-C lowered maximum surface tension, but failed to restore normal function (bottom panel, green). Addition of purified bovine SP-A increased film hysteresis but failed to lower minimum surface tension (bottom panel, blue). Thus, only addition of purified bovine SP-B restored significant interfacial function.
